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In the present state of healthcare, usual medical care is generally given to the already diseased person, while the
key link—personal health monitoring underlain by predictive, preventive, and personalised medicine (PPPM)
techniques that are being intensively elaborated worldwide—is simply missing. It is this link, based on the
recognition of subclinical conditions, prediction, and further preventive measures, that is capable of regulating
morbidity and diminishing the rates of disability among able-bodied population, thus significantly cutting the
traditionally high costs of treating the already diseased people. To achieve the above-mentioned goal—the
elaboration of the PPPM concept and its practical implementation—it is necessary to create a fundamentally new
strategy based upon the subclinical recognition of the signs—bioindicators of cryptic abnormalities long before the
disease clinically manifests itself. The implementation of PPPM programme requires an adjusted technology for the
proper interpretation of diagnostic data, which would allow for the current ‘physician-patient’ model to be
gradually replaced by a novel model, ‘medical advisor-healthy men-at-risk’. This is the reason for an additional need
in organising combinatorial scientific, clinical, training and educational projects in the area of PPPM to elicit the
content of this new branch of medicine.
Keywords: Predictive, preventive, and personalised medicine, Subclinical, Omics, Bioinformatics, Biopredictors,
Biomarkers, Ethics, Policy, Legacy, Economy, Integrative medical approachReview
Introduction
Over the course of its history, medicine has given special
attention to the already diseased individual, focusing on
studying a type of disorder (nosology) rather than one’s
health or the so-called pre-nosological conditions, the lat-
ter being left in the shade. Meanwhile, at present, medi-
cine is undergoing a paradigm shift from the real-time
diagnostics and treatment to prediction and prevention
[1-3].
This major upheaval is expected to transform the nature
of healthcare from reactive to preventive [4]. The changes
will be catalysed by a new system approach to disease that
will trigger the emergence of personalised medicine—a
medicine that focuses on the integrated diagnosis, treat-
ment, and prevention of disease in individual patients
(Figure 1). This change is rooted in new science [5].* Correspondence: dkostushev@gmail.com
2I.M.Sechenov First Moscow State Medical University, Moscow, Russia
Full list of author information is available at the end of the article
© 2012 Bodrova et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe convergence of system approaches to disease, new
measurement and visualisation technologies [6,7], and
new computational and mathematical tools can be
expected to allow our current, largely reactive mode of
medicine, where we wait until the patient becomes ill
before responding, to be replaced over the next 10 to
20 years with predictive, preventive, and personalised
medicine (PPPM) (Figure 2) that will be cost-effective
and increasingly focused on the ‘well-being’ concept
[2,3,5].
It was at the turn of the 1990s that this dramatic turning
point in the view of the role and place of medicine in
healthcare system occurred, following the implementation
of the achievements of innovative omics technologies
(genomics, transcriptomics, proteomics, metabolomics, etc.)
(Figure 3) and bioinformatics (Figure 4) into clinical
medicine which make it possible to penetrate tissues
and organs and create conditions to secure the visual-
isation of lesion foci that is previously unknown to
clinicians [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The scheme depicts the underpinnings of personalised medicine and principle approaches to be included into the PPPM
protocols.
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of PPPM
Omic-based presymptomatic prediction (see Figures 3,
and 4) of an illness and allied events, finer diagnostic
subclassifications, and improved risk assessment tools
applied early in life will permit more-targeted and cost-
effective intervention in children and adults [9].
Genomics
Genomics is a branch of science that deals with the
common principles of genome infrastructure and func-
tion by DNA sequencing and genetic polymorphismFigure 2 The overarching idea of personalised (individualised) medic
preventive measures.analysis (Figures 5 and 6). The latter would provide an
opportunity to develop a panel of PPPM-related algo-
rithms and thereafter identify pharmacotherapeutic tar-
gets as the basis of developing tools of preventive
gene-based therapy [10].
Recent advances in molecular biology have enabled a
more detailed understanding of the impact of genetics as
applicable to a full-term clinical illness and a subclinical
stage of the disease, in particular. Pharmacogenomics is
an allied portion of genomics and is thus a field of study
to examine the impact of genetic variation on the response
to medications. This approach is aimed at tailoring drugine with basic branches aimed at subclinical diagnosis and
Figure 4 Bioinformatics as a valuable tool for processing of large data values in indicative research, genome-wide analysis and large-
scale population studies. (A) Simultaneous genotyping of more than 500,000–1,000,000 SNPs. (B) Initial discovery study with large patient and
control sample collection. (C) Statistical analysis (probability plot for association with a certain disease) and independent replication of top results.
Figure 3 The role of genomics in new target identification and screening of causative mutations.
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Figure 5 The interrelations between the basis of PPPM (genomics, proteomics, and metabolomics) and their application for global
molecular profiling.
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vidual patient, with the potential benefits of increasing
the clinical efficacy and safety of medications [11].
Pharmacogenomics will guide therapeutic decisions and
monitor the response to therapy.
The advances mentioned are converging with the
movement towards consumer-driven health-care and pa-
tient empowerment. Whereas in the past medical testing
was firmly under the control of medical practitioners,
today’s genomic information is increasingly available out-
side the traditional medical settings. In the future, the
primary role of healthcare professionals may be to inter-
pret patients’ DTC genetic test results and advise them
about appropriate follow-up.Figure 6 Four pillars of expertise in bioinformatics.Transcriptomics
The transcriptome is regarded to be a set of all RNA
molecules produced in one or a population of cells. The
transcriptome can thus be seen as a precursor for the
proteome (see below), that is, the entire set of proteins
expressed by a genome.
The study of transcriptomics (see Figure 3), also re-
ferred to as expression profiling, examines the expression
level of mRNAs in a given cell population, often using
high-throughput techniques based on DNA microarray
technology. Also, recent advances in RNAi screening and
next-generation sequencing technologies enable a syner-
gistic application of all of these genomic technologies to
the discovery of predictive biomarkers [12,13].Proteomics
The fundamental role of proteomics (see Figure 3)
belongs to the methods of the identification of individual
proteins and epitopes within these proteins to be of value
for bioprediction. The field of proteomics, or the compre-
hensive analysis and characterisation of all of the proteins
and protein isoforms encoded by the human genome,
may eventually have a great impact on PPPM [14].
It is hoped that recent advances in the understanding
of the genetic aetiologies of common chronic diseases
will improve pharmaceutical development. Thus, perso-
nalised medicine is in many ways simply an extension of
traditional clinical medicine taking advantage of the cut-
ting edge of genetic research [15,16]. In reality, proteo-
mics per se is the continuation of functional genomics
(see Figure 7) and, at the same time, the prologue to the
following section—to metabolomics.
Figure 7 Genome, transcriptome, and proteome in a step-by-step assessment of possible risks and prediction of a latent/progressive
disease.
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Metabolomics illustrates the functional state of the cell
at the level of metabolism on a real-time basis, requiring
the use of the term metabolome, uncustomary at first
sight but reflecting a complex of all metabolic pathways
in the cell at a given moment in time. Specifically, meta-
bolomics (see Figure 3) is the ‘systematic study of the
unique chemical fingerprints that specific cellular pro-
cesses leave behind’, and the study of their small-
molecule metabolite profiles.
One of the challenges for systems biology and func-
tional genomics is to integrate proteomic, transcriptomic,
and metabolomic information to give a more complete
picture of living organisms (Figure 7).
Fundamental science today as applicable to PPPM will
thus demonstrate the following:
1. How the human genome has opened up a broad
spectrum of predictive approaches for both simple
and complex genetic diseases by the analysis of
individual genes, SNPs, and haplotypes
2. How protein and RNA microarrays are providing
new insight into the nature, course, and prognosis of
certain ongoing diseases (e.g., cancer)
3. How autoantibodies (autoAbs) which now are known
to be present years before the clinical onset of a
number of autoimmune diseases (for instance, Type 1
diabetes (T1D), rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE), multiple sclerosis (MS),
etc.) are being used as predictive markers to enter
high-risk subjects into therapeutic intervention trials
[17]. Thus, how is the whole data provided bymetabolomics and, of course, genomics and
proteomics to be comprehended?
Bioinformatics as the essential stone in the overall PPPM
concept
It is bioinformatics that serves to meet this goal by ap-
plying mathematical modelling techniques (see Figure 4).
Bioinformatics deals with algorithms, databases and
information systems, web technologies, artificial intelli-
gence and soft computing, information and computation
theory, structural biology and software engineering, etc.
Bioinformatics generates new knowledge as well as the
computational tools to create that knowledge.
In the near future, genotyping and phenotyping results
combined and consolidated under the aegis of having
undergone computer-assisted processing will be used for
the creation of unified information bases necessary for
personal health biomonitoring, i.e., in terms of PPPM
objectives, based on the principles of bioprediction and
bioprevention through the stage of subclinical diagnos-
tics (Figure 8) [18].
One idea of this medical model is the development
of companion diagnostics, whereby molecular assays
that measure the levels of proteins, genes, or specific
mutations are used to provide a specific therapy for an
individual’s condition by stratifying the disease status,
selecting the proper medication, and tailoring dosages to
the patient’s specific needs. Additionally, such methods
might be used to assess the patient’s risk factors for a
number of conditions and tailor individual preventive
treatments such as nutritional immunology approaches.
In the future, tissue-derived molecular information might
Figure 8 The multi-level graph delineating the relatedness of disease burden with costs and disease irreversibility along with the basic
events in the course of a disease and instruments to be applicable for diagnosis and search for new biomarkers.
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tory, family history, and the data from imaging and other
laboratory tests to develop more effective treatments for
a wider variety of conditions [19].
An understanding and possibly a complete description
of the factors underlying the burden of a disorder and
later on of the disease will give policy makers, healthcare
providers, and educators an opportunity to guide pri-
mary and secondary preventive initiatives at both indi-
vidual and community levels.
Aims, objectives, and tools of subclinical diagnostic
armamentarium
PPPM uses diagnostic tests of newer generations, par-
ticularly genomic, proteomic, and metabolomic biomar-
kers, to individually determine the health conditions a
person is predisposed to and to reveal the agents of the
probable or the already existing pathological processes.
The predictive branch is mainly designed to meet the
interests of healthy individuals, its purpose being to de-
termine whether susceptibility to a particular disease is
increased or not. Preventive medicine is aimed at taking
measures to avoid disease development rather than cure
or treat it on manifestation. Finally, the model of perso-
nalised medicine proposes the customisation of health-
care, with all decisions and practices being tailored to the
individual patient by the mutual integration of clinical in-
formation, stable and dynamic genomics, and molecular
phenotyping through bioinformatics (Figure 1) [20,21].The future impacts of the application of a personalised
medical approach can hardly be overestimated. For in-
stance, it has become clear now that, in order to be suc-
cessful, cancer treatments must be tailored to individual
patients based on specific genetic drivers of tumour
growth, and several preclinical platforms have already
been developed for that purpose. Another example is
drug resistance, which also proves dependent on gene–
drug interactions affecting individual response to therapy.
Generally, there is a multilevel infrastructure to demon-
strate and to operate three levels desirable for providing
optimal subclinical and clinical medical care services:
1. Determining genetic predisposition to a defined
pathology to utilise updated protocols of genotyping.
This step requires the use of such technologies as
genetic polymorphism testing and DNA sequencing,
as well as the analysis of information available from
the genealogical tree, anamnesis morbi, and
anamnesis vitae. Technologically, those goals can be
accomplished by BioChip methodology (every disease
has individual fingerprints and/or molecular
signatures: changes in gene expression/transcription
levels that are indicative of a nosology) (Figure 9)
[22].
2. Individuals selected in the first stage undergo the
second phase of the survey, which uses the target
panel of phenotypic biomarkers (protocols of
phenotyping);
Figure 9 The fundamentals of BioChip methodology.
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responses to drug-based preventive measures is
indispensible during the monitoring of dynamic shifts
in the levels of biomarkers and biopredictors.
There has been much debate over securing the validity
of PPPM-related genetic testing, possible risks, and ben-
efits of PPPM, as well as some ethic issues [23]. Thus,
we still have to answer a number of questions before we
go too far down the PPPM-related path:
 How can the quality and validity of genetic tests be
ensured?
 What are predictive medicine’s actual health
benefits?
 What are the risks and side effects associated with
taking medicine before a person gets sick?
 What are the psychological consequences of being
told you are at risk of developing a certain disease?
 How can third parties, such as employers and
insurance providers, be prevented from using
predictive medicine data in ways that negatively
affect individuals?
Subclinical diagnostics as applicable to particular diseases
There are two typical examples that best illustrate the
specificity of the topic: T1D and MS. The basis of
autoimmune diseases is a universal degenerative and
inflammatory process, which comprises a number of
stages, including the stage of subclinical pathology (see
Figure 10).
Each stage is proved to be determined by a set of
specific parameters, i.e.:
(a) Appearance of anti-islet autoAbs and an upsurge in
the autoAbs titers in T1D, the most importantbiopredictive factor of T1D at the subclinical
stage [24]
(b) Gene expression products of the key (e.g., functional
transcripts) and anti-myelin autoAbs with
proteolytic activity directed towards myelin antigens
(Abs-proteases).
Measuring these allows the physician to assign proper
treatment for persons at risks even at subclinical stage.
The data set harvesting of genomics, proteomics, and
metabolomics of an individual is an important approach
to risk assessment for the relatives of persons with the
diagnosed T1D or MS [25]. We have proposed a universal
model of an autoimmune disease in a view of post-
infectious autoimmune syndrome (PIFAS) (Figure 11),
associated with the underlying disease, as a key factor to
precede clinical manifestation and promote its chronisa-
tion [26].
A spectrum of gene mutations to increase risks of
T1D development is quite well determined. The most
informative genetic markers of T1D from the list above
are HLA-loci, particularly DR4, DR3, DQ, DR2, DR6,
and DR7 (Figure 12), as their certain combinations pro-
mote the progression of PIFAS as a biopredictor of
T1D-related clinical illness at a subclinical stage.
Concerning MS, the most important and informative
gene combinations that have to date been associated
with MS include 509 TGFB1, C DRB*18(3), CTLA4*G
and 238TNF*B1, 308TNF*A2, and CTLA4*G. Such
combinations support the formation of PIFAS-related
signs at the subclinical stage, which are highly informative
biopredictors to monitor a process of demyelination [27].
Proteomics, as applicable to the prediction of T1D, is
no less important. T1D patients begin expressing auto-
Abs as early as 5–10 years before the clinical onset of
the disease. Most of the data available indicate that this
Figure 10 Aetiopathogenesis of T1D and critical events in dysregulation of immune system leading to β-cell loss and clinical
manifestation.
Figure 11 Two major mechanisms of PIFAS: molecular mimicry and adjuvant effect that are usually the common causes of most
autoimmune diseases.
Bodrova et al. The EPMA Journal 2012, 3:16 Page 8 of 11
http://www.epmajournal.com/content/3/1/16
Figure 12 The distribution of diabetogenic and protective potentials of HLA class II in different populations. Green columns refer to low
risk (diabetoprotective); yellow columns, medium risk (moderately diabetogenic); and red columns, highly diabetogenic.
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celiac disease, and MS. Early evidence suggests that this
phenomenon is also true to many of the 40–80 other
autoimmune diseases identified so far [28,29]. The direct
application of the aforementioned issues is just the
combined gene- and phenotyping of persons at risks
for biopredictors of both categories (genomics- and
proteomics-related ones simultaneously) which would sig-
nificantly raise the index of predictivity (up to 85%–90%),
thus improving the selection of persons at risks for fur-
ther drug-based therapeutic prevention [30].
Preventive drug-based treatment as applicable to
particular diseases
The strategy of drug-based therapeutic prevention in
managing autoimmune diseases should include two
critical points to make the subclinical diagnosis fina-
lised and confirmed:
1. Quenching (arrest/blockage) autoagression and thus
autoimmune chronic inflammation
2. Restoration of tissue- and organ-related
morphofunctional architectonics.
The latter can successfully be achieved through the
practical realisation of a number of strategies, particularly
cell- and/or gene-based therapy, allogenic or xenogeneic
transplantation, and stem cell technologies [31,32]. In
addition, a principally new technology that holds promise
in modern medicine is the application of Abs-proteases
as novel tools for drug-based therapeutic prevention.Perspectives of PPPM as a tool in the global restructuring
of the healthcare services
System approach to the formation of an innovative infra-
structure regarding predictive and preventive algorithms
is an ultimate approach that will contribute to the mod-
ernisation of the world healthcare services drastically.
Our challenge is that the new guidelines should create
the robust juristic and economic platforms for advanced
medical services utilising the cost-effective models of risk
assessments followed by tailored preventive treatments
focused on the precursor stages of chronic diseases.
Recently developed economical models clearly demon-
strate the effectiveness of PPPM, if introduced as the
integrative medical approach into the healthcare ser-
vices [30].
Individuals to be under regular monitoring that helps
to detect pathological shifts at subclinical stages of a dis-
ease have a higher life expectancy and are able-bodied
up to 8–15 years more than those under traditional
treatment. This means that the society saves more than
US$20,000–40,000 per person annually [33].
However, above all, it is the people’s recognition of the
responsibility for their own health and for the health of
their children and their active involvement in preventive
measures that can provide the strengthening of public
health and the country’s biosafety through medical
establishments. Therefore, with no government-directed
and civil support, this national idea will remain without
proper attention in spite of its perspective and social
orientation [23]. This project requires the solution of
several priorities.
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meet all society needs for the individual health to be
protected—regulations of the state insurance as applic-
able to PPPM, financing channels of this sector including
both budgetary and private sources, regulations of the
doctor–patient relationships and, finally, the acquaint-
ance with a new discipline to be fitted into the frame
of the overall infrastructure of healthcare services [34].
Second, because of the novelty of this area, it is neces-
sary not only to improve but also radically change the
system of medical training, improving the level of their
skills, expanding the technological spectrum of benefits
for the population, and designing new approaches to
build the academic schools of new generations.
There is a need to educate much more physicians and
nurses in conducting hi-tech medical research. Moreover,
there is a need to educate more clinicians to perform
systematic reviews of previous research data. Only in
this way are we able to close the gaps in our knowledge
unveiling the outcome and benefits of PPPM.
Furthermore, there seems to be a need for more deep
(in a stepwise manner) advising and mentoring students
and younger colleagues of medical science and health
services. The existing medical education would strongly
need (apart of graduate and post-graduate levels) pre-
graduate (higher school) level to disclose the mysteries
of the evidence-based medicine. Thus, faculty advisors
would have to advise a wide range of students and
junior colleagues, from pre-graduate, through predegree
undergraduates to postdoctoral students and junior fac-
ulty and researchers.
On the policy front, we must make sure that policies
with respect to privacy, non-discrimination, and access
to health insurance, all critical for any healthcare system,
are aligned to maximise both the protections and the
benefits to patients. The opportunity arises for unusual
strategic partnerships between the government, the
academy, and the commercial sectors to appear. The
societal, ethical, and healthcare policy issues attendant to
the anticipated changes will be profound. These changes
must also be planned so that the barriers to the delivery
of the benefits enabled by technical advances do not pre-
vent their adoption.
Conclusions
Meanwhile today, we are at the verge of global changes
that illustrate the progress of medical healthcare. It
becomes focused not on the therapy of an illness but
rather on the protection of individual health. Also,
PPPM would thus promise to sharply reverse the ever-
escalating costs of healthcare-introducing diagnosis to
stratify patients and disease, less expensive approaches to
drug discovery, preventive medicine and wellness, and
exponentially cost measurement technologies. PPPM alsopromises to improve patient outcomes and to empower
both the patient and the physician [35]. We must acceler-
ate this transformation by promoting the necessary sci-
entific research and at the same time dealing with the
societal challenges presented by PPPM. The healthcare
industry, public policy sector, and consumer industries
will of necessity be required to develop new and creative
business models and products. There is a unique oppor-
tunity now to enable and accelerate a change by eliminat-
ing the key technical and societal (ethical, societal, policy,
legal, economic, etc.) barriers that will prevent the full
realisation of the revolution of PPPM. No doubt, the next
generations will speak about the twenty-first century as a
time when medicine became preventive and personified
and its outcomes—predictive and guaranteed.
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